-
On the 22nd September 2017 Granules OmniChem Limited (GOC) received the Establishment Inspection Report (EIR) from the US-FDA
-
Louvain-la-Neuve: New address from 01/10/2017
-
Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency and Antibody Drug Conjugate Commercial Facility
-
Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line
-
CEO J. David Enloe Awarded ‘Most Admired CEO’
-
Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing
-
Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing
-
Ajinomoto Group Acquires All Shares of GeneDesign, a Nucleic Acid Drug CDMO, to Accelerate Expansion of the Contract Business for Oligonucleotides.
-
Biologics candidate manufactured using Ajinomoto Co., Inc.’s CORYNEX® Protein Expression System enters clinical trials for the first time
-
Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies
-
Ajinomoto Althea, Inc. Expands Its Capacity of Fill Finish Manufacturing with Addition of Second Shift
-
Ajinomoto Althea, Inc. Launches Process and Analytical Development Services for Antibody Drug Conjugates (ADCs) Therapeutics